Promising new radiation therapy targets Hard-to-Treat prostate cancer

NCT ID NCT06879041

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug (AZD2284) that delivers radiation directly to prostate cancer cells. It is for men whose cancer has spread and no longer responds to hormone therapy. The main goals are to check safety and find the right dose, while also measuring how well it shrinks tumors and controls the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Research Site
NOT_YET_RECRUITING

Palo Alto, California, 94304, United States
Research Site
NOT_YET_RECRUITING

San Diego, California, 92103, United States
Research Site
RECRUITING

Miami, Florida, 33165, United States
Research Site
RECRUITING

Tampa, Florida, 33612, United States
Research Site
RECRUITING

Chicago, Illinois, 60637, United States
Research Site
NOT_YET_RECRUITING

Metairie, Louisiana, 70006, United States
Research Site
RECRUITING

Boston, Massachusetts, 02215, United States
Research Site
NOT_YET_RECRUITING

Rochester, Minnesota, 55902, United States
Research Site
RECRUITING

Omaha, Nebraska, 68130, United States
Research Site
NOT_YET_RECRUITING

New York, New York, 10032, United States
Research Site
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
Research Site
NOT_YET_RECRUITING

Portland, Oregon, 97239, United States
Research Site
RECRUITING

East Melbourne, 3002, Australia
Research Site
NOT_YET_RECRUITING

CapeTown, 7925, South Africa
Research Site
WITHDRAWN

Durban, 4013, South Africa
Research Site
NOT_YET_RECRUITING

Pretoria, 181, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.